Brooks Laboratories

Chandigarh, India Founded: 2002 • Age: 24 yrs Listed
Manufacturer of pharmaceutical injectables, tablets, and oral suspensions

About Brooks Laboratories

Brooks Laboratories is a publicly listed company based in Chandigarh (India) founded in 2002. Manufacturer of pharmaceutical injectables, tablets, and oral suspensions. The company has 499 employees. Its chief executive, as recorded, is Rajnish Kumar Bedi. Its Indian entity Brooks Laboratories Limited reported revenue of ₹106 Cr. Brooks Laboratories offers products and services including Antibiotics and Injections. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Founded in 2002 and based in Chandigarh, India, the company operates in the pharmaceutical sector. Formulations across therapeutic areas such as antibiotics and pain management are developed, manufactured, and marketed. Products, including injectables, tablets, and oral suspensions, are distributed domestically and internationally. GMP certifications and accreditations are held, with manufacturing processes maintained under strict quality control standards.

  • Headquarters Chandigarh, India
  • Employees 499
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website brookslabs.net
  • Social LinkedIn Instagram
  • Legal Name Brooks Laboratories Limited
Key Metrics
  • Market Cap
    ₹197 Cr

    BROOKS · NSE

  • Share Price
    ₹67.30

    +0.51% today

  • Revenue
    ₹85.74 Cr

    FY 2025-26 · +3.9% YoY

  • EBITDA
    ₹7.07 Cr

    Margin 8.2%

  • Net Profit
    ₹24.30 Cr

    FY 2025-26 · +343.2% YoY

  • P/E (TTM)
    59.5x

    P/B 1.1x

  • Employee Count
    499

Products & Services of Brooks Laboratories

Brooks Laboratories offers a comprehensive portfolio of products and services, including Antibiotics and Injections.

Antibiotics
Pharmaceutical Products

Antibiotics and related formulations are manufactured and distributed for therapeutic use.

Injections
Pharmaceutical Products

Liquid, dry powder, and lyophilized injections are produced for various medical applications.

Board of directors of Brooks Laboratories Limited (Brooks Laboratories)

Brooks Laboratories Limited is the primary company behind Brooks Laboratories. The board of Brooks Laboratories Limited currently have 6 directors; the longest-serving is Jitendrapratap Rambahadur Singh, appointed in 2022. 22 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jitendrapratap Rambahadur Singh
DIN 09796568
Whole-time director23 Nov 20223 yrs 11 moBrooks Laboratories Limited
Durga Shankar Maity
DIN 03136361
Whole-time director07 Jul 20233 yrs 4 moBrooks Laboratories Limited
Bhushan Singh Rana
DIN 10289384
Whole-time director23 Aug 20233 yrs 2 moBrooks Laboratories Limited
Lalit Mahajan
DIN 03270819
Director07 Aug 20242 yrs 3 moBrooks Laboratories Limited
Usha Singh
DIN 10706734
Director07 Aug 20242 yrs 3 moBrooks Laboratories Limited
Manav Mahajan
DIN 10721554
Director28 Sep 20242 yrs 1 moBrooks Laboratories Limited

People of Brooks Laboratories

1 people are tracked at Brooks Laboratories (1 in leadership); the tracked headcount is 499.

NameRoleGroup
Chairman & CEOLeadership
Premium access

Complete people profiles for Brooks Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Brooks Laboratories

Brooks Laboratories is a publicly listed company on the NSE with ticker symbol BROOKS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Sep 2011
  • Listed onBSE: 533543 · NSE: BROOKS
  • Listed entityBrooks Laboratories Limited
  • Exchange sectorHealth technology
  • ISININE650L01011
  • Share price₹68.72 (+6.11% on the day) · 2026-10-14
  • Market capitalisation₹191 Cr
  • Price to earnings15.3
  • EPS (diluted, trailing year)₹4.49
  • Volume (last session)214,839

Financials of Brooks Laboratories

Exchange-reported figures of Brooks Laboratories Limited, the listed company behind Brooks Laboratories (NSE: BROOKS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹85.74 Cr
+3.9% YoY
EBITDA
₹7.07 Cr
+187.9% YoY
Profit After Tax
₹24.30 Cr
+343.2% YoY
Net Worth
₹123 Cr
+25.0% YoY
Total Assets
₹133 Cr
+24.0% YoY
Total Debt
₹8.52 Cr
+12.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth+3.9%+3.9%+25.8%-30.7%+18.0%-
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Balance sheet
Total assets13310772.6882.49162112
Net worth12398.1165.5973.9587.4979.15
Total debt8.527.585.646.5125.2631.38
Cash & bank7.551.250.691.083.811.70
Net working capital22.0117.2413.290.4927.430.69
Cash flow
Cash from operations9.292.63(9.80)(14.49)(37.44)4.46
Cash from investing(2.92)(45.14)0.180.49(24.91)(5.13)
Cash from financing0.1742.439.7211.4164.071.16
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.181.355.326.137.150.620.03
EBITDA(2.06)(1.34)0.680.742.523.12(1.25)(1.49)
EBITDA margin-10.7%-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax72.92(1.79)1.535.517.989.58(1.28)(2.12)
Tax5.320.000.000.000.000.000.180.00
Net profit67.60(1.79)1.535.517.989.58(1.46)(2.12)
EPS (₹)22.95(0.61)0.521.872.713.25(0.54)(0.82)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Balance sheet
Total assets13112476.6365.3173.1174.37128
Net worth12111569.5356.7865.0064.2198.41
Total debt8.527.585.646.515.978.4027.64
Cash & bank7.551.250.691.081.080.881.53
Net working capital22.0117.2413.290.496.696.717.82
Cash flow
Cash from operations9.292.63(9.80)0.553.12(0.90)(9.39)
Cash from investing(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Cash from financing0.1742.439.72(0.21)(4.22)1.319.61
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.180.440.130.390.220.620.03
Total expenses18.9321.1019.5315.8320.9322.3921.7418.94
EBITDA0.321.860.680.742.523.121.581.58
EBITDA margin+1.7%+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax75.301.410.620.322.242.651.550.95
Tax5.320.000.000.000.000.000.180.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.181.355.326.137.150.620.03
EBITDA(2.06)(1.34)0.680.742.523.12(1.25)(1.49)
EBITDA margin-10.7%-5.8%+3.4%+4.5%+10.7%+12.2%-5.4%-7.3%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax72.92(1.79)1.535.517.989.58(1.28)(2.12)
Tax5.320.000.000.000.000.000.180.00
Net profit67.60(1.79)1.535.517.989.58(1.46)(2.12)
EPS (₹)22.95(0.61)0.521.872.713.25(0.54)(0.82)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue85.7482.5679.4963.2091.1877.25
Revenue growth+3.9%+3.9%+25.8%-30.7%+18.0%-
Other income19.950.880.920.570.800.74
Total expenses78.6790.6097.3592.9210576.72
Employee cost14.6212.4510.0916.0016.8512.04
EBITDA7.07(8.04)(17.86)(29.72)(14.27)0.53
EBITDA margin+8.3%-9.7%-22.5%-47.0%-15.7%+0.7%
Depreciation1.591.601.777.037.357.14
Interest0.841.030.842.183.103.10
Profit before tax24.59(9.79)(19.55)(38.36)(23.92)(8.97)
Tax0.000.180.03(7.32)(4.59)10.38
Net profit24.30(9.99)(19.59)(21.25)(11.44)(19.31)
Net profit margin+28.3%-12.1%-24.6%-33.6%-12.6%-25.0%
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.70
Reserves & surplus93.2068.6539.3449.2562.7954.45
Shareholders' funds (net worth)12398.1165.5973.9587.4979.15
Minority interest0.000.000.000.0046.830.00
Secured loans7.286.065.045.6624.2131.38
Unsecured loans1.241.520.600.851.050.00
Total debt8.527.585.646.5125.2631.38
Total liabilities13310772.6882.49162112
Assets
Gross block26.0025.1523.2722.83143133
Net block14.5213.9813.6715.00110108
Capital work in progress1.190.000.000.0015.110.83
Investments92.3473.5542.9164.030.060.02
Inventories11.029.209.6111.3027.5223.60
Sundry debtors16.1119.9916.3212.7517.6613.70
Cash & bank balances7.551.250.691.083.811.70
Loans & advances2.733.434.432.4712.198.36
Total current assets37.4133.8731.0527.6061.1847.36
Total current liabilities15.4016.6317.7627.1133.7546.67
Net working capital22.0117.2413.290.4927.430.69
Total assets13310772.6882.49162112
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash0.040.130.022.610.880.40
Net cash from operating activities9.292.63(9.80)(14.49)(37.44)4.46
Net cash from investing activities(2.92)(45.14)0.180.49(24.91)(5.13)
Net cash from financing activities0.1742.439.7211.4164.071.16
Net change in cash6.54(0.08)0.10(2.58)1.720.49
Closing cash7.551.250.691.083.811.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+3.9%+3.9%+25.8%-30.7%+18.0%-
EBITDA growth+187.9%+55.0%+39.9%-108.3%-2792.5%-
PBT growth+9998.0%+49.9%+49.0%-60.4%-166.7%+9997.0%
Net income growth+343.2%+49.0%+7.8%-85.8%+40.8%-
Revenue CAGR (3Y)+10.7%-3.3%+1.0%---
EBITDA CAGR (3Y)--17.4%----
Profitability & leverage
Net income margin+28.7%-12.1%-24.6%-49.1%-21.2%-25.1%
Return on capital employed-0.0%0.0%0.0%0.0%0.0%
Return on net worth-0.0%0.0%0.0%0.0%0.0%
Debt / equity-0.080.090.200.400.40
Long-term debt / equity-0.010.010.070.170.18
Interest cover15.33-10.68-4.28-5.93-14.34-46.90
Efficiency & per share
Fixed asset turnover-3.413.450.760.660.58
Inventory turnover-8.787.603.263.563.27
Debtors turnover-4.555.474.165.815.64
EPS (₹)8.35(3.38)(7.46)(8.46)(4.57)(7.84)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)41.6433.3024.9929.9435.4232.04
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue19.2522.9620.2116.5723.4525.5123.3220.52
Revenue growth (YoY)-17.9%-10.0%-13.3%-19.3%+12.8%+42.3%--
Other income75.680.180.440.130.390.220.620.03
Total expenses18.9321.1019.5315.8320.9322.3921.7418.94
EBITDA0.321.860.680.742.523.121.581.58
EBITDA margin+1.7%+8.1%+3.4%+4.5%+10.7%+12.2%+6.8%+7.7%
Depreciation0.450.420.410.390.390.390.390.38
Interest0.250.210.090.160.280.300.260.28
Profit before tax75.301.410.620.322.242.651.550.95
Tax5.320.000.000.000.000.000.180.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue85.7482.5679.4955.5476.9777.2769.69
Revenue growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
Other income1.170.880.920.120.950.960.41
Total expenses78.6777.5876.2361.3575.0976.3373.61
Employee cost14.6212.4510.0910.6510.8812.0411.16
EBITDA7.074.983.26(5.81)1.880.94(3.92)
EBITDA margin+8.3%+6.0%+4.1%-10.5%+2.4%+1.2%-5.6%
Depreciation1.591.601.771.721.497.096.65
Interest0.841.030.840.770.673.253.35
Profit before tax5.813.231.57(8.18)0.67(8.44)(13.51)
Tax0.000.180.030.000.007.1510.86
Net profit5.523.031.53(8.19)0.41(15.53)(23.19)
Net profit margin+6.4%+3.7%+1.9%-14.8%+0.5%-20.1%-33.3%
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital29.4629.4626.2524.7024.7024.7024.70
Reserves & surplus91.3985.6143.2832.0840.3039.5173.71
Shareholders' funds (net worth)12111569.5356.7865.0064.2198.41
Secured loans7.286.065.045.664.928.4026.88
Unsecured loans1.241.520.600.851.050.000.76
Total debt8.527.585.646.515.978.4027.64
Total liabilities13112476.6365.3173.1174.37128
Assets
Gross block26.0025.1523.2722.8321.0719.64133
Net block14.5213.9813.6715.0015.1414.96113
Capital work in progress1.190.000.000.001.120.020.11
Investments90.5390.5246.8646.8546.8446.810.02
Inventories11.029.209.6111.3016.5912.3813.77
Sundry debtors16.1119.9916.3212.7515.039.5915.56
Cash & bank balances7.551.250.691.081.080.881.53
Loans & advances2.733.434.432.474.342.497.05
Total current assets37.4133.8731.0527.6037.0425.3437.91
Total current liabilities15.4016.6317.7627.1130.3518.6330.09
Net working capital22.0117.2413.290.496.696.717.82
Total assets13112476.6365.3173.1174.37128
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.040.130.020.080.060.402.50
Net cash from operating activities9.292.63(9.80)0.553.12(0.90)(9.39)
Net cash from investing activities(2.92)(45.14)0.18(0.40)1.12(0.74)(2.33)
Net cash from financing activities0.1742.439.72(0.21)(4.22)1.319.61
Net change in cash6.54(0.08)0.10(0.06)0.02(0.33)(2.10)
Closing cash7.551.250.691.081.080.881.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.9%+3.9%+43.1%-27.8%-0.4%+10.9%-
EBITDA growth+42.0%+52.8%+156.1%-409.0%+100.0%+124.0%-
PBT growth+79.9%+105.7%+9998.0%-+9998.0%+37.5%+9.6%
Net income growth+82.2%+98.0%+118.7%-2097.6%+102.6%+33.0%-
Revenue CAGR (3Y)+15.6%+2.4%+1.0%-7.3%+11.8%+11.5%+6.6%
EBITDA CAGR (3Y)-+38.4%+51.4%+14.0%---
Profitability & leverage
Net income margin+6.8%+3.7%+1.9%-14.7%+0.9%-20.2%-35.0%
Return on capital employed+4.3%+3.2%+2.7%0.0%+1.2%0.0%-7.7%
Return on net worth+4.0%+2.4%+1.9%0.0%+0.5%0.0%-24.0%
Debt / equity0.070.070.100.100.110.220.29
Long-term debt / equity0.010.010.010.010.020.080.13
Interest cover15.3330.4756.38-10.23171.79-52.85-31.69
Efficiency & per share
Fixed asset turnover3.353.413.452.533.781.020.53
Inventory turnover8.488.787.603.985.315.915.85
Debtors turnover4.754.555.474.006.256.145.17
EPS (₹)1.971.040.58(3.31)0.27(6.31)(9.87)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)41.0239.0626.4922.9826.3125.9939.84

Web traffic of Brooks Laboratories

The website of Brooks Laboratories (brookslabs.net) receives about 1.2K visits a month.

  • Monthly visits
    1.2K

    ▼ 8.4% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Brooks Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Brooks Laboratories

Premium access

Complete news archive for Brooks Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Brooks Laboratories

Brooks Laboratories was founded in 2002.

Brooks Laboratories is headquartered in Chandigarh, India.

Rajnish Kumar Bedi is the CEO of Brooks Laboratories, as recorded in our data.

Brooks Laboratories has 499 employees.

The primary company behind Brooks Laboratories, Brooks Laboratories Limited, reported revenue of ₹106 Cr for FY 2026, up 4% year on year.

Founded in 2002 and based in Chandigarh, India, the company operates in the pharmaceutical sector. Formulations across therapeutic areas such as antibiotics and pain management are developed, manufactured, and marketed. Products, including injectables, tablets, and oral suspensions, are distributed domestically and internationally. GMP certifications and accreditations are held, with manufacturing processes maintained under strict quality control standards.

Brooks Laboratories offers Antibiotics and Injections.

Yes, Brooks Laboratories is publicly traded on NSE under the ticker symbol BROOKS.

Brooks Laboratories operates through Brooks Laboratories Limited.

The legal entities of Brooks Laboratories currently have 8 directors, including Prashant Rathi, Jitendrapratap Rambahadur Singh, Krutika Mohan Rane and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available